Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Study: Vioxx Risk Lingered After Discontinued Use

Posted by Chrissie Cole
Monday, October 13, 2008 11:43 PM EST
Category: Major Medical
Tags: FDA & Prescription Drugs, Vioxx, Merck, Dangerous and Defective Drugs, Arthritis, Aleve, Heart Attack, APPROVe Study,


IMAGE SOURCE: © Merck Web site. "Where patients come first"

When Vioxx was taken off the market in 2004, due to concerns that it increased the risk of heart attack, stroke and death – many were under the assumption that discontinuing use would end the associated health risks.

But, now, a new study suggests that the “risks increased nearly twofold, and persisted for a year or more after stopping use of Vioxx,” said Dr. Robert Bresalier, co-author and professor of medicine at the M.D. Anderson Cancer Center in Houston, Texas.

“The upside is, the data suggests the risk does not last and goes back toward normal after a year,” he said.

Another issue raised by this analysis was how soon the risk started after beginning to use Vioxx.

Several doctors, long critical of Merck and its reporting of Vioxx studies, have contended that increased cardiovascular risks started within just a few months of use and persisted after discontinuing use.

Researchers and many experts believe long-term use of most non-aspirin pain killers in the same drug class – also known as non-steroidal anti-inflammatory drugs (NSAIDs) such as Aleve/Naproxen – also increases the risk of heart attack stroke and death to a certain extent.

Merck continues to argue that cardiac risks did not increase until after 18 months or more of use – a basis of its approach to fight thousands of pending lawsuits filed by people claiming they have suffered harm by Vioxx.

The study is published in October 14 early online edition of The Lancet.

Last year, Merck inked a $4.85 billion deal to settle thousands of claims for strokes, heart attacks and deaths allegedly caused by the drug.

The “APPROVe” study was intended to show that Vioxx, promoted as a pain reliever with lower gastrointestinal risks than other anti-inflammatory drugs, could prevent the recurrence of colon cancer.

Merck halted the study early and withdrew the drug from the market on September 30, 2004, when data showed a double risk of cardiovascular complications and death in the group of patients taking Vioxx, over those taking a placebo.

In the year after the 2,487 patient-study was discontinued, eight researchers found – 34 people taking the drug and 18 taking a placebo suffered a heart attack – a 94 percent greater risk in Vioxx users.

19 Vioxx users suffered a stroke compared to nine people on placebo, for a risk slightly more than double. In total, 76 Vioxx users and 46 placebo users suffered a stroke, heart attack, blood clot or death during that follow-up year.

The increased complications are nearly the same as the findings during the three-year trial and the first two weeks after the study was first halted.

Merck came under fire after publishing its first analysis from the APPROVe Study, in 2005. The company later admitted to using the wrong statistical methods of analysis and the editors of the New England Journal published a correction in 2006 stating the risk of heart problems was increased throughout the duration of time people were taking the drug.

The analysis helps to further establish not only the risk of Vioxx, but the temporal duration,” said Dr. Eric J. Topol, director of the Scripps Translational Science Institute. “We now have compelling data that the risk extends a year after stopping the drug,” he said.

However, Dr. Topol, one of the first to raise concerns about Vioxx, is unsure that this is a class effect of all cox-2 inhibitors.

In other Vioxx news, eight states, along with Florida, are suing Merck & Co alleging deceptive marketing of the recalled painkiller Vioxx.

Florida’s Attorney General Bill McCollum says the state wants to be reimbursed for more than $80 million spent on health programs, such as Florida’s Medicaid program, which included Vioxx as an approved drug. Patients taking it for pain would be reimbursed for the prescription. #

1 Comment

Anonymous User
Posted by Debbie Cox
Tuesday, October 14, 2008 11:27 AM EST

Does yesterday's Lancet information (death could occur as long as a year or longer afer discontinued use) about users who used VIOXX for 3 years or longer change the statute of limitations for those now reaizing that they WERE injured but up until now were being excluded by the "failure to die within 14 day" rule? Also, does it lend much more strength to the fact that many side effects at time of death, are those same side effects that come from polonged use? i.e. caused by VIOXX also?

My husband passed away in Idaho. Are there anay attorneys who will take this case now? Up until now, it has been cnsidered useless (in spite of the fatal MI) because of the 14 days.

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes